TG THERAPEUTICS INC (TGTX)

US88322Q1085 - Common Stock

15.57  +0.13 (+0.84%)

After market: 15.2408 -0.33 (-2.11%)

Fundamental Rating

5

Overall TGTX gets a fundamental rating of 5 out of 10. We evaluated TGTX against 592 industry peers in the Biotechnology industry. TGTX has an average financial health and profitability rating. TGTX shows excellent growth, but is valued quite expensive already.



5

1. Profitability

1.1 Basic Checks

In the past year TGTX was profitable.
In the past year TGTX has reported a negative cash flow from operations.
In the past 5 years TGTX reported 4 times negative net income.
In the past 5 years TGTX always reported negative operating cash flow.

1.2 Ratios

TGTX's Return On Assets of 3.85% is amongst the best of the industry. TGTX outperforms 95.58% of its industry peers.
Looking at the Return On Equity, with a value of 7.90%, TGTX belongs to the top of the industry, outperforming 95.75% of the companies in the same industry.
TGTX has a better Return On Invested Capital (5.90%) than 95.92% of its industry peers.
Industry RankSector Rank
ROA 3.85%
ROE 7.9%
ROIC 5.9%
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 5.43%, TGTX belongs to the best of the industry, outperforming 95.41% of the companies in the same industry.
The Operating Margin of TGTX (8.82%) is better than 95.41% of its industry peers.
TGTX has a better Gross Margin (93.94%) than 95.75% of its industry peers.
Industry RankSector Rank
OM 8.82%
PM (TTM) 5.43%
GM 93.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TGTX is destroying value.
Compared to 1 year ago, TGTX has more shares outstanding
The number of shares outstanding for TGTX has been increased compared to 5 years ago.
TGTX has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 3.98 indicates that TGTX is not in any danger for bankruptcy at the moment.
The Altman-Z score of TGTX (3.98) is better than 75.00% of its industry peers.
A Debt/Equity ratio of 0.62 indicates that TGTX is somewhat dependend on debt financing.
TGTX's Debt to Equity ratio of 0.62 is on the low side compared to the rest of the industry. TGTX is outperformed by 75.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z 3.98
ROIC/WACC0.65
WACC9.12%

2.3 Liquidity

TGTX has a Current Ratio of 5.92. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Current ratio (5.92) which is comparable to the rest of the industry.
TGTX has a Quick Ratio of 5.18. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.18, TGTX is in line with its industry, outperforming 55.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.92
Quick Ratio 5.18

8

3. Growth

3.1 Past

TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.68%, which is quite impressive.
TGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 8245.39%.
Measured over the past years, TGTX shows a very strong growth in Revenue. The Revenue has been growing by 335.01% on average per year.
EPS 1Y (TTM)100.68%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q74.36%
Revenue 1Y (TTM)8245.39%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Revenue growth Q2Q43871%

3.2 Future

The Earnings Per Share is expected to grow by 246.33% on average over the next years. This is a very strong growth
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.52% yearly.
EPS Next Y-1222%
EPS Next 2Y599.71%
EPS Next 3Y425.17%
EPS Next 5Y246.33%
Revenue Next Year14.17%
Revenue Next 2Y36.5%
Revenue Next 3Y39.59%
Revenue Next 5Y42.52%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

2

4. Valuation

4.1 Price/Earnings Ratio

TGTX is valuated quite expensively with a Price/Earnings ratio of 1557.00.
TGTX's Price/Earnings ratio is rather cheap when compared to the industry. TGTX is cheaper than 93.71% of the companies in the same industry.
When comparing the Price/Earnings ratio of TGTX to the average of the S&P500 Index (26.42), we can say TGTX is valued expensively.
TGTX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 1557
Fwd PE N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TGTX is valued cheaply inside the industry as 94.22% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 103.83

4.3 Compensation for Growth

TGTX's earnings are expected to grow with 425.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y599.71%
EPS Next 3Y425.17%

0

5. Dividend

5.1 Amount

TGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

TG THERAPEUTICS INC

NASDAQ:TGTX (3/27/2024, 8:00:01 PM)

After market: 15.2408 -0.33 (-2.11%)

15.57

+0.13 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.40B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 1557
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.85%
ROE 7.9%
ROCE
ROIC
ROICexc
ROICexgc
OM 8.82%
PM (TTM) 5.43%
GM 93.94%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.92
Quick Ratio 5.18
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)100.68%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1222%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8245.39%
Revenue growth 3Y1059.22%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y